Answers are grounded in this paper and cite their sources.
In this study, we describe a response signal of cTnT to tofersen treatment, which supports the value of cTnT as an independent biomarker in ALS. These results contribute to the notion that cTnT may provide additional value as a progression and treatment response biomarker in ALS complementary to NfL and warrant further investigation.
No takes yet. Share an insight, caveat, or question.
Bernsen et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: